U.S. Communications Stock News

NasdaqGM:PUBM
NasdaqGM:PUBMMedia

Why PubMatic (PUBM) Is Up 18.7% After AI-Driven CTV Revenue Surge Outpaces Expectations

PubMatic reported its third-quarter 2025 results last week, showing revenue of US$67.96 million and a net loss of US$6.45 million, both wider than the prior year period, but exceeding adjusted earnings and revenue expectations from analysts. The company spotlighted more than 50% year-over-year Connected TV ad revenue growth and emphasized the impact of its AI-driven innovations, developed with NVIDIA, which have contributed to increased publisher revenues and marketplace...
NasdaqGS:DNUT
NasdaqGS:DNUTHospitality

Krispy Kreme (DNUT): Evaluating the Stock After Its Bold Menu Expansion and Nostalgic Marketing Push

Krispy Kreme (DNUT) is shaking things up this month with an expanded menu, rolling out nine brand new doughnut flavors and growing its everyday line-up to sixteen options. This refresh comes at the same time as a marketing push that channels a classic 1990s tune, sparking fresh buzz around the brand. See our latest analysis for Krispy Kreme. The new menu launch and nostalgia-fueled marketing push come at a time when Krispy Kreme’s momentum is especially volatile. While the company’s 1-month...
NYSE:LVWR
NYSE:LVWRAuto

Reassessing LiveWire Group (LVWR) Valuation Following Widened 2025 Loss Guidance and Quarterly Earnings Update

LiveWire Group (LVWR) updated its guidance for 2025, now expecting a wider operating loss range of $72 million to $77 million, up from its previous estimate. This announcement was released together with the company’s third-quarter earnings results and provided key updates for investors. See our latest analysis for LiveWire Group. LiveWire Group’s announcement of a wider expected operating loss for 2025 appears to have weighed on sentiment even as quarterly losses improved from last year. The...
NasdaqCM:ENGN
NasdaqCM:ENGNBiotechs

Could a Shift in enGene (ENGN) Trial Endpoints Reveal New Priorities in Its Clinical Strategy?

enGene Holdings recently reported additional preliminary efficacy data from its pivotal Phase 2 LEGEND trial for detalimogene voraplasmid in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer, along with a protocol amendment changing the primary clinical endpoint after discussions with the FDA. This update reveals that earlier patients in the study experienced a lower 12-month complete response rate compared to FDA-approved therapies, leading to significant...
NYSE:AVNT
NYSE:AVNTChemicals

Can Avient’s (AVNT) Margin Gains Reveal New Strengths in Its Specialty Materials Portfolio?

Avient Corporation recently reported its third-quarter 2025 financial results, posting sales of US$806.5 million and net income of US$32.6 million, both slightly below the previous year, alongside margins that improved due to effective cost controls. The company expects fourth-quarter sales to show modest improvement over the third quarter, supported by growth in its Specialty Engineered Materials segment and new product innovations. We'll explore how Avient’s improved profit margins and...
NasdaqGS:ALKT
NasdaqGS:ALKTSoftware

Does Alkami Technology’s Recent Bank Partnerships Signal a Shift in Valuation for 2025?

Wondering if now is the right time to buy Alkami Technology? With so many opinions out there, getting straight to the heart of whether the stock is good value can make all the difference. After climbing 8.3% in the last week, Alkami Technology is still down 10.7% over the past month and has fallen 44% year-to-date, pointing to both volatility and shifting market sentiment. Recent headlines have focused on Alkami’s expansion into new financial technology services and...
NasdaqGS:KLTR
NasdaqGS:KLTRSoftware

Assessing Kaltura (KLTR) Valuation Following New Earnings Results and Updated Full-Year Guidance

Kaltura (KLTR) just shared its quarterly earnings and new guidance for the rest of the year. The update offers fresh insights into the company’s financial health and what investors might expect in the coming months. See our latest analysis for Kaltura. Kaltura’s share price showed a burst of short-term momentum lately, climbing 15.2% over the last month after a much slower start to the year. Despite the latest guidance and buyback update, the overall one-year total shareholder return is still...
NasdaqGS:OM
NasdaqGS:OMMedical Equipment

Could Tablo’s Real-World Success Shift Outset Medical’s (OM) Growth Trajectory Despite Lowered Guidance?

Outset Medical recently reported third quarter results, showing revenue of US$29.43 million and a reduced net loss of US$17.84 million compared to the previous year, while also lowering its annual revenue guidance for 2025. New research presented at the American Society of Nephrology's 2025 Kidney Week highlighted strong real-world outcomes for the Tablo system, including a large reduction in complications and high staff satisfaction across 1 million treatments in approximately 750...